

# **Certificate of Analysis for NR-51605**

## Pseudomonas aeruginosa, Strain MRSN 351791

### Catalog No. NR-51605

This reagent is the tangible property of the U.S. Government.

### **Product Description:**

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 351791 was isolated from human urine in 2015 as part of a surveillance program in the United States. P. aeruginosa, strain MRSN 351791 was deposited as sensitive to amikacin, ceftazidime, cefepime, gentamicin, imipenem, meropenem and piperacillin/tazobactam and resistant to aztreonam, ciprofloxacin and levofloxacin, with intermediate resistance to tobramycin.

Lot: 70025116<sup>1</sup> Manufacturing Date: 02AUG2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology <sup>2</sup>	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Irregular, slight peaked, undulate,
		opaque and cream (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	P. aeruginosa (≥ 89%)	P. aeruginosa (99%)
Antibiotic Susceptibility Profile <sup>3</sup>		
VITEK® (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Sensitive	Sensitive (8 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Sensitive	Sensitive (4 µg/mL)
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Sensitive	Sensitive (2 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Amikacin	Sensitive	Sensitive (4-8 µg/mL)
Gentamicin	Sensitive	Sensitive (2 µg/mL)
Tobramycin	Intermediate	Sensitive (≤ 1 μg/mL) <sup>4</sup>
Ciprofloxacin	Resistant	Sensitive (≤ 0.25 µg/mL) <sup>5</sup>
Levofloxacin	Resistant	Sensitive (0.5 μg/mL) <sup>6</sup>
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	80 μg/mL <sup>7</sup>
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	100% sequence identity to
(~ 1400 base pairs)	P. aeruginosa, strain MRSN 351791	P. aeruginosa, strain MRSN 351791
	(GenBank: RXUE01000124.1)	(GenBank: RXUE01000124.1)
Purity (post-freeze) <sup>8</sup>	Growth consistent with expected	Growth consistent with expected
	colony morphology	colony morphology
Viability (post-freeze) <sup>2</sup>	Growth	Growth

<sup>&</sup>lt;sup>1</sup>NR-51605 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

<sup>&</sup>lt;sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>&</sup>lt;sup>4</sup>P. aeruginosa, strain MRSN 351791 was deposited as intermediate to tobramycin, but showed a MIC of ≤ 1 μg/mL (interpreted as sensitive) for tobramycin during QC testing. Testing was performed in duplicate.

<sup>&</sup>lt;sup>5</sup>P. aeruginosa, strain MRSN 351791 was deposited as resistant to ciprofloxacin, but showed a MIC of ≤ 0.25 μg/mL (interpreted as sensitive) for ciprofloxacin during QC testing. Testing was performed in duplicate.



# **Certificate of Analysis for NR-51605**

<sup>6</sup>P. aeruginosa, strain MRSN 351791 was deposited as resistant to levofloxacin, but showed a MIC of 0.5 μg/mL (interpreted as sensitive) for levofloxacin during QC testing. Testing was performed in duplicate.

<sup>8</sup>Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

17 DEC 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

<sup>&</sup>lt;sup>7</sup>Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa.*" <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.